ANKRD37: A Potential Drug Target and Biomarker for Low Density Lipoprotein Receptor-Related Protein Binding

Target Name: ANKRD37

NCBI ID: G353322

ANKRD37

ANKRD37: A Potential Drug Target and Biomarker for Low Density Lipoprotein Receptor-Related Protein Binding

Introduction

Low density lipoprotein (LDL) cholesterol is a major risk factor for the development of cardiovascular diseases, such as heart failure, stroke, and myocardial infarction. Approximately 75% of the total cholesterol in the blood comes from LDL cholesterol, and LDL cholesterol levels are often used as a diagnostic marker for hyperlipidemia. ANKRD37, a protein that is known to interact with LDL cholesterol, has been identified as a potential drug target and biomarker for LDL cholesterol-related diseases.

An Overview of ANKRD37

ANKRD37 (short for ANK-related protein 37) is a 21-kDa protein that is expressed in various tissues, including liver, muscle, and placenta. It is a member of the ANK-related protein (AP-1) family, which includes several related proteins, including ANKR1, ANKR2, ANKR3, and ANKR4. ANKRD37 is characterized by a N-terminal 伪-helix, a C-terminal 伪-sheet, and a variable number of transmembrane domains.

The ANKRD37 protein has been shown to interact with LDL cholesterol in a variety of cell types and contexts. For example, ANKRD37 has been shown to enhance the expression of LDL cholesterol in human peripheral blood mononuclear cells (PBMCs), and to inhibit the clearance of LDL cholesterol in these cells. These effects are consistent with the idea that ANKRD37 may play a role in the regulation of LDL cholesterol levels.

An Potential Role for ANKRD37 as a Drug Target

The ANKRD37 protein has been identified as a potential drug target for several reasons. First, ANKRD37 has been shown to interact with LDL cholesterol in a variety of cell types, which suggests that it may play a role in the regulation of LDL cholesterol levels. Second , ANKRD37 has been shown to enhance the expression of LDL cholesterol in PBMCs, which may contribute to the regulation of LDL cholesterol levels in these cells. Finally, ANKRD37 has been shown to inhibit the clearance of LDL cholesterol in PBMCs, which may also contribute to the regulation of LDL cholesterol levels in these cells.

The Potential clinical applications of ANKRD37 as a drug target are vast. For example, ANKRD37-targeted drugs could be used to treat hyperlipidemia by reducing the levels of LDL cholesterol in the blood. Such drugs could be used in combination with lifestyle modifications, such as diet and exercise, to achieve better lipid control. Additionally, ANKRD37-targeted drugs could be used to treat other conditions that are associated with high LDL cholesterol levels, such as cardiovascular diseases and metabolic disorders.

An Potential Role for ANKRD37 as a Biomarker

The ANKRD37 protein has also been shown to serve as a potential biomarker for LDL cholesterol levels. The ANKRD37 protein has been shown to be expressed in various tissues and cell types, including blood vessels, liver, and muscle. Additionally, the ANKRD37 protein has been shown to be involved in the regulation of LDL cholesterol levels in these tissues. For example, ANKRD37 has been shown to enhance the expression of LDL cholesterol in PBMCs, which may contribute to the regulation of LDL cholesterol levels in these cells.

The potential use of ANKRD37 as a biomarker for

Protein Name: Ankyrin Repeat Domain 37

The "ANKRD37 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ANKRD37 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets